Gene Correction for SCID-X1 In Long-Term Hematopoietic Stem Cells




Journal Title

Journal ISSN

Volume Title


Nature Publishing Group


Gene correction in human long-term hematopoietic stem cells (LT-HSCs) could be an effective therapy for monogenic diseases of the blood and immune system. Here we describe an approach for X-linked sSevere cCombined iImmunodeficiency (SCID-X1) using targeted integration of a cDNA into the endogenous start codon to functionally correct disease-causing mutations throughout the gene. Using a CRISPR-Cas9/AAV6 based strategy, we achieve up to 20% targeted integration frequencies in LT-HSCs. As measures of the lack of toxicity we observe no evidence of abnormal hematopoiesis following transplantation and no evidence of off-target mutations using a high-fidelity Cas9 as a ribonucleoprotein complex. We achieve high levels of targeting frequencies (median 45%) in CD34 + HSPCs from six SCID-X1 patients and demonstrate rescue of lymphopoietic defect in a patient derived HSPC population in vitro and in vivo. In sum, our study provides specificity, toxicity and efficacy data supportive of clinical development of genome editing to treat SCID-Xl. ©2019 The Author(s).



Cd28 Antigens



Pavel-Dinu, M., V. Wiebking, B. T. Dejene, W. Srifa, et al. 2019. "Gene correction for SCID-X1 in long-term hematopoietic stem cells." Nature Communications 10(1): art. 1634, doi: 10.1038/s41467-019-09614-y